Check out our comprehensive educational activities here

Venetoclax plus azacytidine, venetoclax plus decitabine or venetoclax plus low-dose cytarabine; how do you determine which combination therapy to use on your patients with AML?

There are three FDA-approved combinations for patients with AML. In this activity, Dr. Jonas discusses how to determine which combination therapy is the most appropriate for specific patients.

Published on December 1, 2021 in Treatment

Where does the combination of venetoclax with decitabine or azacitidine or LDAC fit in the treatment paradigm for AML?

In this activity, Dr. Jonas discusses combination therapies for patients with AML and where they fit in the treatment paradigm.

Published on November 22, 2021 in Treatment

What is the best approach to the therapy of patients with P53-mutated AML?

Dr. Amir Fathi provides his approach to best therapy of patients with P53-mutated AML.

Published on November 10, 2021 in Treatment

What is the approach to the management of differentiation syndrome arising after therapy with IDH inhibitors?

In this activity, Dr. Fathi explains the manifestations of therapy with IDH inhibitors relative to the development of differentiation syndrome.

Published on November 3, 2021 in Treatment

What would be the best approach to the upfront therapy of IDH1/2 mutated AML among patients who are not eligible for intensive therapy?

Join Dr. Amir Fathi as he describes the best approach to upfront therapy for patients who are not eligible for traditional intensive therapy.

Published on October 28, 2021 in Treatment

Are patients who relapse after first-generation FLT3 inhibitors likely to respond to second-generation FLT3 inhibitors?

In this activity, Dr. Short describes FLT3 inhibitors after relapse and if they should be given alone or in combination.

Published on October 20, 2021 in Treatment

What are the prognostic implications of TP53 mutations in AML and what key clinical trials show promise for future treatment?

Join Dr. Short as he explains the prognostic implications of TP53 mutations in AML, including those with variant allele frequency.

Published on October 13, 2021 in Treatment

Why is it important to repeat genomic analysis at the time of AML relapse and what mutation should be tested?

In this activity, Dr. Nicholas Short discusses the approved drugs for various genomic abnormalities, including those in clinical trials.

Published on October 6, 2021 in Treatment

What is the efficacy of high-intensity therapy and stem cell transplant in older adults compared with younger patients?

Join Dr. Foran as he explains stem cell transplant in older and younger adults with AML.

Published on September 22, 2021 in Treatment

What are the current treatment options for older secondary acute myeloid leukemia (sAML) patients with myelodysplasia (MDS)-related changes?

Join Dr. Lancet as he discusses the treatment options for older secondary acute myeloid leukemia patients with myelodysplasia-related changes.

Published on September 15, 2021 in Treatment